A phase II trial of temsirolimus in second-line metastatic urothelial cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-12

AUTHORS

H. Gerullis, C. Eimer, T. H. Ecke, E. Georgas, C. Freitas, S. Kastenholz, C. Arndt, C. Heusch, T. Otto

ABSTRACT

This phase II trial assessed temsirolimus, an inhibitor of mammalian target of rapamycin (mTOR), as second-line therapy in patients with metastatic transitional carcinoma of the urothelium (TCCU) after failure of platinum containing therapy. From June/2009 to June/2011, we enrolled 15 patients in this trial. Primary endpoint was overall survival, as secondary endpoints we defined time to disease progression, safety and QoL along treatment. Patients with progressive TCCU after prior platinum-based chemotherapy received weekly 25 mg of temsirolimus for 8 weeks. Evaluation for response was accomplished every 8 weeks according to the RECIST criteria, QoL assessment was done every 4 weeks using the QLQ-C30 questionnaire, adverse events (AEs) were recorded and graded using NCI-CTC criteria. Fifteen patients were enrolled in this study, of whom 14 (93%) were available for activity, safety and QoL assessment. We treated 10 (71%) male and 4 female (29%) patients. Median age was 64,7 years (45-76). Patients received on average 13 (3-15) infusions of temsirolimus. As per protocol, no sufficient benefit on overall survival was observed, we early stopped the study after 14 patients. Median time to progression was 2.5 months (77 days), median overall survival was 3.5 months (107 days). Four patients with stable disease were observed. QoL assessment along treatment revealed a reduction of EORTC-QLQ-C30, Global Health Status subscale, from initial 7.86 to 5.00. Temsirolimus was well tolerated. As Grade 3-4 adverse events, we observed fatigue (n=2), leukopenia (n=2) and thrombopenia (n=2). All other adverse events were graded 1-2 in nature. Temsirolimus seems to have poor activity in patients with progressive metastasized TCCU after failure of platinum containing first-line therapy. More... »

PAGES

2870-2876

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12032-012-0216-x

DOI

http://dx.doi.org/10.1007/s12032-012-0216-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1048653555

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22447503


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Transitional Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sirolimus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urinary Bladder Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Duisburg-Essen", 
          "id": "https://www.grid.ac/institutes/grid.5718.b", 
          "name": [
            "Department of Urology, Lukas Hospital, Preussenstrasse 84, 41464, Neuss, Germany", 
            "West German Cancer Center (WTZ), University of Essen, Essen, Germany", 
            "German Centre for Assessment and Evaluation of Innovative Techniques in Medicine (DZITM), Neuss, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gerullis", 
        "givenName": "H.", 
        "id": "sg:person.0734236041.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734236041.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Lukaskrankenhaus", 
          "id": "https://www.grid.ac/institutes/grid.416164.0", 
          "name": [
            "Department of Urology, Lukas Hospital, Preussenstrasse 84, 41464, Neuss, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eimer", 
        "givenName": "C.", 
        "id": "sg:person.01323676132.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01323676132.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Urology, HELIOS Hospital, Bad Saarow, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ecke", 
        "givenName": "T. H.", 
        "id": "sg:person.014716707747.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014716707747.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Lukaskrankenhaus", 
          "id": "https://www.grid.ac/institutes/grid.416164.0", 
          "name": [
            "Department of Urology, Lukas Hospital, Preussenstrasse 84, 41464, Neuss, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Georgas", 
        "givenName": "E.", 
        "id": "sg:person.01066272724.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066272724.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Lukaskrankenhaus", 
          "id": "https://www.grid.ac/institutes/grid.416164.0", 
          "name": [
            "Department of Internal Medicine I, Lukas Hospital, Neuss, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Freitas", 
        "givenName": "C.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "German Centre for Assessment and Evaluation of Innovative Techniques in Medicine (DZITM), Neuss, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kastenholz", 
        "givenName": "S.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "German Centre for Assessment and Evaluation of Innovative Techniques in Medicine (DZITM), Neuss, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arndt", 
        "givenName": "C.", 
        "id": "sg:person.0646710472.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646710472.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Lukaskrankenhaus", 
          "id": "https://www.grid.ac/institutes/grid.416164.0", 
          "name": [
            "Department of Urology, Lukas Hospital, Preussenstrasse 84, 41464, Neuss, Germany", 
            "German Centre for Assessment and Evaluation of Innovative Techniques in Medicine (DZITM), Neuss, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heusch", 
        "givenName": "C.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Duisburg-Essen", 
          "id": "https://www.grid.ac/institutes/grid.5718.b", 
          "name": [
            "Department of Urology, Lukas Hospital, Preussenstrasse 84, 41464, Neuss, Germany", 
            "West German Cancer Center (WTZ), University of Essen, Essen, Germany", 
            "German Centre for Assessment and Evaluation of Innovative Techniques in Medicine (DZITM), Neuss, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Otto", 
        "givenName": "T.", 
        "id": "sg:person.01116365472.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116365472.09"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1097/jto.0b013e318155a439", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000605125"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.37.7002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001764075"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.25.4599", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007036818"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.20.5534", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008285055"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2407-10-368", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008418244", 
          "https://doi.org/10.1186/1471-2407-10-368"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdq398", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020204461"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.10.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026558254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1053/j.seminoncol.2006.12.008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028301104"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/mou.0b013e32832eb473", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029806876"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/mou.0b013e32832eb473", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029806876"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/mou.0b013e32832eb473", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029806876"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0b013e328347a86a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030638021"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0b013e328347a86a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030638021"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1464-410x.2004.04574.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031077604"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.23.622", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038090213"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.21265", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040207329"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.21265", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040207329"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0021-9681(61)90060-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043596267"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.08.185", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043632450"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-005-1444-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050400962", 
          "https://doi.org/10.1007/s10637-005-1444-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-005-1444-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050400962", 
          "https://doi.org/10.1007/s10637-005-1444-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/01621459.1958.10501452", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1058299418"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/85.5.365", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059818446"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/or.2011.1146", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071531259"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4161/cbt.8.24.9987", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072295447"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.10.3173", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074528556"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1990.8.6.1050", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078446050"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0022-5347(17)39548-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078760810"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.28.15_suppl.e15087", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083945746"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.29.15_suppl.4606", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083947983"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-12", 
    "datePublishedReg": "2012-12-01", 
    "description": "This phase II trial assessed temsirolimus, an inhibitor of mammalian target of rapamycin (mTOR), as second-line therapy in patients with metastatic transitional carcinoma of the urothelium (TCCU) after failure of platinum containing therapy. From June/2009 to June/2011, we enrolled 15 patients in this trial. Primary endpoint was overall survival, as secondary endpoints we defined time to disease progression, safety and QoL along treatment. Patients with progressive TCCU after prior platinum-based chemotherapy received weekly 25 mg of temsirolimus for 8 weeks. Evaluation for response was accomplished every 8 weeks according to the RECIST criteria, QoL assessment was done every 4 weeks using the QLQ-C30 questionnaire, adverse events (AEs) were recorded and graded using NCI-CTC criteria. Fifteen patients were enrolled in this study, of whom 14 (93%) were available for activity, safety and QoL assessment. We treated 10 (71%) male and 4 female (29%) patients. Median age was 64,7 years (45-76). Patients received on average 13 (3-15) infusions of temsirolimus. As per protocol, no sufficient benefit on overall survival was observed, we early stopped the study after 14 patients. Median time to progression was 2.5 months (77 days), median overall survival was 3.5 months (107 days). Four patients with stable disease were observed. QoL assessment along treatment revealed a reduction of EORTC-QLQ-C30, Global Health Status subscale, from initial 7.86 to 5.00. Temsirolimus was well tolerated. As Grade 3-4 adverse events, we observed fatigue (n=2), leukopenia (n=2) and thrombopenia (n=2). All other adverse events were graded 1-2 in nature. Temsirolimus seems to have poor activity in patients with progressive metastasized TCCU after failure of platinum containing first-line therapy.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s12032-012-0216-x", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094524", 
        "issn": [
          "1357-0560", 
          "1559-131X"
        ], 
        "name": "Medical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "29"
      }
    ], 
    "name": "A phase II trial of temsirolimus in second-line metastatic urothelial cancer", 
    "pagination": "2870-2876", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "e7c6f2a14003fff199d63e983224093b44b9e548e09a2f116a2c54c821a1ba65"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22447503"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9435512"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12032-012-0216-x"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1048653555"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12032-012-0216-x", 
      "https://app.dimensions.ai/details/publication/pub.1048653555"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T16:45", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8669_00000524.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs12032-012-0216-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12032-012-0216-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12032-012-0216-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12032-012-0216-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12032-012-0216-x'


 

This table displays all metadata directly associated to this object as RDF triples.

256 TRIPLES      21 PREDICATES      65 URIs      32 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12032-012-0216-x schema:about N0aa87803bc5c4323b467d1267bdf04d2
2 N375feafa44f74e6b9c87ac09053ed0a7
3 N43e849ebe4de4590940226d674883b48
4 N7ea5183bd4f24e4ab1ed29521459f26f
5 N940e5fed24c846bba7ff3350c2ee8361
6 N995bbea5a1cc424ab1bce1ac8f9eb25c
7 N9e57a1b16d4f4e419a0504189c572dc0
8 Nb5fd3a77d1ad46759de8e03b1a384fcf
9 Ncbdfd75defab42aa8d8f15d9d84575ee
10 Ndba722766be74f869e7732361d65c167
11 Ndfddfc722d5a4468840924505dd947fc
12 anzsrc-for:11
13 anzsrc-for:1103
14 schema:author Na0d91b0e1e1147d0801fcfcb0a3079c9
15 schema:citation sg:pub.10.1007/s10637-005-1444-0
16 sg:pub.10.1186/1471-2407-10-368
17 https://doi.org/10.1002/cncr.21265
18 https://doi.org/10.1016/0021-9681(61)90060-1
19 https://doi.org/10.1016/j.ejca.2008.10.026
20 https://doi.org/10.1016/s0022-5347(17)39548-4
21 https://doi.org/10.1053/j.seminoncol.2006.12.008
22 https://doi.org/10.1080/01621459.1958.10501452
23 https://doi.org/10.1093/annonc/mdq398
24 https://doi.org/10.1093/jnci/85.5.365
25 https://doi.org/10.1097/cad.0b013e328347a86a
26 https://doi.org/10.1097/jto.0b013e318155a439
27 https://doi.org/10.1097/mou.0b013e32832eb473
28 https://doi.org/10.1111/j.1464-410x.2004.04574.x
29 https://doi.org/10.1200/jco.1990.8.6.1050
30 https://doi.org/10.1200/jco.1999.17.10.3173
31 https://doi.org/10.1200/jco.2004.08.185
32 https://doi.org/10.1200/jco.2005.23.622
33 https://doi.org/10.1200/jco.2008.20.5534
34 https://doi.org/10.1200/jco.2009.25.4599
35 https://doi.org/10.1200/jco.2010.28.15_suppl.e15087
36 https://doi.org/10.1200/jco.2011.29.15_suppl.4606
37 https://doi.org/10.1200/jco.2011.37.7002
38 https://doi.org/10.3892/or.2011.1146
39 https://doi.org/10.4161/cbt.8.24.9987
40 schema:datePublished 2012-12
41 schema:datePublishedReg 2012-12-01
42 schema:description This phase II trial assessed temsirolimus, an inhibitor of mammalian target of rapamycin (mTOR), as second-line therapy in patients with metastatic transitional carcinoma of the urothelium (TCCU) after failure of platinum containing therapy. From June/2009 to June/2011, we enrolled 15 patients in this trial. Primary endpoint was overall survival, as secondary endpoints we defined time to disease progression, safety and QoL along treatment. Patients with progressive TCCU after prior platinum-based chemotherapy received weekly 25 mg of temsirolimus for 8 weeks. Evaluation for response was accomplished every 8 weeks according to the RECIST criteria, QoL assessment was done every 4 weeks using the QLQ-C30 questionnaire, adverse events (AEs) were recorded and graded using NCI-CTC criteria. Fifteen patients were enrolled in this study, of whom 14 (93%) were available for activity, safety and QoL assessment. We treated 10 (71%) male and 4 female (29%) patients. Median age was 64,7 years (45-76). Patients received on average 13 (3-15) infusions of temsirolimus. As per protocol, no sufficient benefit on overall survival was observed, we early stopped the study after 14 patients. Median time to progression was 2.5 months (77 days), median overall survival was 3.5 months (107 days). Four patients with stable disease were observed. QoL assessment along treatment revealed a reduction of EORTC-QLQ-C30, Global Health Status subscale, from initial 7.86 to 5.00. Temsirolimus was well tolerated. As Grade 3-4 adverse events, we observed fatigue (n=2), leukopenia (n=2) and thrombopenia (n=2). All other adverse events were graded 1-2 in nature. Temsirolimus seems to have poor activity in patients with progressive metastasized TCCU after failure of platinum containing first-line therapy.
43 schema:genre research_article
44 schema:inLanguage en
45 schema:isAccessibleForFree false
46 schema:isPartOf N0a27308bbb0c4110b6c3172a0f40ab6f
47 N5d311db559294444bbf5fdaa50f57948
48 sg:journal.1094524
49 schema:name A phase II trial of temsirolimus in second-line metastatic urothelial cancer
50 schema:pagination 2870-2876
51 schema:productId N05be3f1555d6471f9c07a4a473d4bc9a
52 N913029ddb7824a3c9994cdc2b7cb310c
53 Naf02fa5c798146aab452d8c5f35f34e7
54 Nb01afaacb68941fc82b6bc2a086e8c50
55 Nca5a5b634b6347ecae192c0293084ced
56 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048653555
57 https://doi.org/10.1007/s12032-012-0216-x
58 schema:sdDatePublished 2019-04-10T16:45
59 schema:sdLicense https://scigraph.springernature.com/explorer/license/
60 schema:sdPublisher Na54d6cead1d34922a9cc5d2d9926c594
61 schema:url http://link.springer.com/10.1007%2Fs12032-012-0216-x
62 sgo:license sg:explorer/license/
63 sgo:sdDataset articles
64 rdf:type schema:ScholarlyArticle
65 N01fa4d2f203e497dbcaa84163220b3ab rdf:first N8ab69d8643604561a226ec010baf8850
66 rdf:rest Nf61af8a52391433bb01e50ac037775a8
67 N05be3f1555d6471f9c07a4a473d4bc9a schema:name pubmed_id
68 schema:value 22447503
69 rdf:type schema:PropertyValue
70 N0a27308bbb0c4110b6c3172a0f40ab6f schema:issueNumber 4
71 rdf:type schema:PublicationIssue
72 N0aa87803bc5c4323b467d1267bdf04d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Female
74 rdf:type schema:DefinedTerm
75 N0ab951b449bd4be1abe9235ca6199c3a rdf:first sg:person.01116365472.09
76 rdf:rest rdf:nil
77 N0fcd00e788f94220803863c8ce06acfd schema:affiliation https://www.grid.ac/institutes/grid.416164.0
78 schema:familyName Freitas
79 schema:givenName C.
80 rdf:type schema:Person
81 N375feafa44f74e6b9c87ac09053ed0a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Antineoplastic Agents
83 rdf:type schema:DefinedTerm
84 N43e849ebe4de4590940226d674883b48 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Protein Kinase Inhibitors
86 rdf:type schema:DefinedTerm
87 N5d311db559294444bbf5fdaa50f57948 schema:volumeNumber 29
88 rdf:type schema:PublicationVolume
89 N7ea5183bd4f24e4ab1ed29521459f26f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Humans
91 rdf:type schema:DefinedTerm
92 N81f25303b05047e4aa9a7e8f9b7acfc2 rdf:first sg:person.01066272724.78
93 rdf:rest Ned0aef8d615a466aac4db249b142748d
94 N8ab69d8643604561a226ec010baf8850 schema:affiliation Nfde265c9df1f46b191270143cff75906
95 schema:familyName Kastenholz
96 schema:givenName S.
97 rdf:type schema:Person
98 N8b2d9e59e1924041b93b43e0d7bbe224 schema:name Department of Urology, HELIOS Hospital, Bad Saarow, Germany
99 rdf:type schema:Organization
100 N913029ddb7824a3c9994cdc2b7cb310c schema:name doi
101 schema:value 10.1007/s12032-012-0216-x
102 rdf:type schema:PropertyValue
103 N940e5fed24c846bba7ff3350c2ee8361 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Male
105 rdf:type schema:DefinedTerm
106 N995bbea5a1cc424ab1bce1ac8f9eb25c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Urinary Bladder Neoplasms
108 rdf:type schema:DefinedTerm
109 N9b9e036e68ea4f25a23ff79d2fe2e2f0 schema:name German Centre for Assessment and Evaluation of Innovative Techniques in Medicine (DZITM), Neuss, Germany
110 rdf:type schema:Organization
111 N9e57a1b16d4f4e419a0504189c572dc0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Sirolimus
113 rdf:type schema:DefinedTerm
114 Na0d91b0e1e1147d0801fcfcb0a3079c9 rdf:first sg:person.0734236041.49
115 rdf:rest Nc995fb75848f4fc7a6b3790b905754d6
116 Na27d31a25be44f1b902125d6aab6ca9b rdf:first sg:person.014716707747.02
117 rdf:rest N81f25303b05047e4aa9a7e8f9b7acfc2
118 Na54d6cead1d34922a9cc5d2d9926c594 schema:name Springer Nature - SN SciGraph project
119 rdf:type schema:Organization
120 Naf02fa5c798146aab452d8c5f35f34e7 schema:name dimensions_id
121 schema:value pub.1048653555
122 rdf:type schema:PropertyValue
123 Nb01afaacb68941fc82b6bc2a086e8c50 schema:name nlm_unique_id
124 schema:value 9435512
125 rdf:type schema:PropertyValue
126 Nb4d534a82f3b48f9b85e79d9fbcd9e4a schema:affiliation https://www.grid.ac/institutes/grid.416164.0
127 schema:familyName Heusch
128 schema:givenName C.
129 rdf:type schema:Person
130 Nb5fd3a77d1ad46759de8e03b1a384fcf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Aged
132 rdf:type schema:DefinedTerm
133 Nc0176614fb7740ac8d59f57059c9aa2c rdf:first Nb4d534a82f3b48f9b85e79d9fbcd9e4a
134 rdf:rest N0ab951b449bd4be1abe9235ca6199c3a
135 Nc995fb75848f4fc7a6b3790b905754d6 rdf:first sg:person.01323676132.98
136 rdf:rest Na27d31a25be44f1b902125d6aab6ca9b
137 Nca5a5b634b6347ecae192c0293084ced schema:name readcube_id
138 schema:value e7c6f2a14003fff199d63e983224093b44b9e548e09a2f116a2c54c821a1ba65
139 rdf:type schema:PropertyValue
140 Ncbdfd75defab42aa8d8f15d9d84575ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Quality of Life
142 rdf:type schema:DefinedTerm
143 Ndba722766be74f869e7732361d65c167 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Middle Aged
145 rdf:type schema:DefinedTerm
146 Ndfddfc722d5a4468840924505dd947fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Carcinoma, Transitional Cell
148 rdf:type schema:DefinedTerm
149 Ned0aef8d615a466aac4db249b142748d rdf:first N0fcd00e788f94220803863c8ce06acfd
150 rdf:rest N01fa4d2f203e497dbcaa84163220b3ab
151 Nf61af8a52391433bb01e50ac037775a8 rdf:first sg:person.0646710472.50
152 rdf:rest Nc0176614fb7740ac8d59f57059c9aa2c
153 Nfde265c9df1f46b191270143cff75906 schema:name German Centre for Assessment and Evaluation of Innovative Techniques in Medicine (DZITM), Neuss, Germany
154 rdf:type schema:Organization
155 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
156 schema:name Medical and Health Sciences
157 rdf:type schema:DefinedTerm
158 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
159 schema:name Clinical Sciences
160 rdf:type schema:DefinedTerm
161 sg:journal.1094524 schema:issn 1357-0560
162 1559-131X
163 schema:name Medical Oncology
164 rdf:type schema:Periodical
165 sg:person.01066272724.78 schema:affiliation https://www.grid.ac/institutes/grid.416164.0
166 schema:familyName Georgas
167 schema:givenName E.
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066272724.78
169 rdf:type schema:Person
170 sg:person.01116365472.09 schema:affiliation https://www.grid.ac/institutes/grid.5718.b
171 schema:familyName Otto
172 schema:givenName T.
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116365472.09
174 rdf:type schema:Person
175 sg:person.01323676132.98 schema:affiliation https://www.grid.ac/institutes/grid.416164.0
176 schema:familyName Eimer
177 schema:givenName C.
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01323676132.98
179 rdf:type schema:Person
180 sg:person.014716707747.02 schema:affiliation N8b2d9e59e1924041b93b43e0d7bbe224
181 schema:familyName Ecke
182 schema:givenName T. H.
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014716707747.02
184 rdf:type schema:Person
185 sg:person.0646710472.50 schema:affiliation N9b9e036e68ea4f25a23ff79d2fe2e2f0
186 schema:familyName Arndt
187 schema:givenName C.
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646710472.50
189 rdf:type schema:Person
190 sg:person.0734236041.49 schema:affiliation https://www.grid.ac/institutes/grid.5718.b
191 schema:familyName Gerullis
192 schema:givenName H.
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734236041.49
194 rdf:type schema:Person
195 sg:pub.10.1007/s10637-005-1444-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050400962
196 https://doi.org/10.1007/s10637-005-1444-0
197 rdf:type schema:CreativeWork
198 sg:pub.10.1186/1471-2407-10-368 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008418244
199 https://doi.org/10.1186/1471-2407-10-368
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1002/cncr.21265 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040207329
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1016/0021-9681(61)90060-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043596267
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1016/j.ejca.2008.10.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026558254
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1016/s0022-5347(17)39548-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078760810
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1053/j.seminoncol.2006.12.008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028301104
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1080/01621459.1958.10501452 schema:sameAs https://app.dimensions.ai/details/publication/pub.1058299418
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1093/annonc/mdq398 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020204461
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1093/jnci/85.5.365 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059818446
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1097/cad.0b013e328347a86a schema:sameAs https://app.dimensions.ai/details/publication/pub.1030638021
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1097/jto.0b013e318155a439 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000605125
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1097/mou.0b013e32832eb473 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029806876
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1111/j.1464-410x.2004.04574.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1031077604
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1200/jco.1990.8.6.1050 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078446050
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1200/jco.1999.17.10.3173 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074528556
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1200/jco.2004.08.185 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043632450
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1200/jco.2005.23.622 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038090213
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1200/jco.2008.20.5534 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008285055
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1200/jco.2009.25.4599 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007036818
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1200/jco.2010.28.15_suppl.e15087 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083945746
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1200/jco.2011.29.15_suppl.4606 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083947983
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1200/jco.2011.37.7002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001764075
242 rdf:type schema:CreativeWork
243 https://doi.org/10.3892/or.2011.1146 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071531259
244 rdf:type schema:CreativeWork
245 https://doi.org/10.4161/cbt.8.24.9987 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072295447
246 rdf:type schema:CreativeWork
247 https://www.grid.ac/institutes/grid.416164.0 schema:alternateName Lukaskrankenhaus
248 schema:name Department of Internal Medicine I, Lukas Hospital, Neuss, Germany
249 Department of Urology, Lukas Hospital, Preussenstrasse 84, 41464, Neuss, Germany
250 German Centre for Assessment and Evaluation of Innovative Techniques in Medicine (DZITM), Neuss, Germany
251 rdf:type schema:Organization
252 https://www.grid.ac/institutes/grid.5718.b schema:alternateName University of Duisburg-Essen
253 schema:name Department of Urology, Lukas Hospital, Preussenstrasse 84, 41464, Neuss, Germany
254 German Centre for Assessment and Evaluation of Innovative Techniques in Medicine (DZITM), Neuss, Germany
255 West German Cancer Center (WTZ), University of Essen, Essen, Germany
256 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...